Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Ardelyx, Inc.NASDAQ: ARDX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $20.19M rose 40.8% year over year, ahead of the +33.9% change in trailing-twelve-month research & development. Sequentially, it fell 8.0% from the prior quarter. Over 3 fiscal years it compounded at +24.8% a year.

Context

  • Research & development amounted to 16.8% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +40.8% holds above the trailing-twelve-month pace of +33.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.19M-8.0% QoQ
Last fiscal yearDec 2025
$68.47M+30.9% YoY
LTMMar 2026
$74.32M+33.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+40.8%——
1 year+30.9%——
3-year CAGR+24.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
68.47M USD
Year-over-year change
+30.9%
4-year CAGR
-6.9%

Research & Development vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's LTM Mar 2026 research & development of $74.32M is the 2nd highest of the 5 companies compared; the peer median is $49.64M.
  • Its year-over-year change of +33.9% is the 2nd highest of 5, against a peer median of +28.3%.
  • Research & development amounts to 17.4% of revenue for ARDX, versus a peer median of 28.9%.
ARDX Competitors Peer median
Research & Development for ARDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MAZEMaze Therapeutics, Inc.LTM Mar 2026$114.57M +28.4%+7.1%572.9%
ARDXArdelyx, Inc.LTM Mar 2026$74.32M +33.9%+24.8%17.4%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$67.09M +78.1%-27.8%28.9%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$32.2M +26.3%+14.1%10.2%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$26.95M +28.1%+46.4%—
Peer median (excluding ARDX) $49.64M+28.3%+10.6%28.9%

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.1M52.16M124.46M333.62M407.32M
Cost of Revenue1M4.12M17.8M50.56M42.6M
Gross Profit9.1M48.04M106.66M283.06M364.72M
Gross Margin90.1%92.1%85.7%84.8%89.5%
Research & Development91.14M35.2M35.54M52.32M68.47M
Selling, General & Admin72.3M76.6M134.4M258.69M337.23M
Operating Expenses163.44M111.8M169.94M311.01M405.7M
Depreciation & Amortization2.81M1.14M1.29M2.06M3.06M
EBITDA(150.85M)(60.98M)(55.35M)(16.71M)(29.17M)
EBITDA Margin-1494.0%-116.9%-44.5%-5.0%-7.2%
Operating Income(154.35M)(63.76M)(63.28M)(27.95M)(40.98M)
Operating Margin-1528.6%-122.2%-50.8%-8.4%-10.1%
Interest Income00000
Interest Expense4.5M5.07M8.87M20.09M28.4M
Other Income / Expenses(3.82M)(3.44M)(2.24M)(10.92M)(19.65M)
Income Before Tax(158.16M)(67.2M)(65.52M)(38.87M)(60.63M)
Pre-Tax Margin-1566.4%-128.8%-52.6%-11.7%-14.9%
Income Tax Expense4K8K547K266K969K
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Net Margin-1566.5%-128.9%-53.1%-11.7%-15.1%
EPS (Basic)(1.52)(0.42)(0.30)(0.17)(0.26)
EPS (Diluted)(1.52)(0.42)(0.30)(0.17)(0.26)
Weighted Avg Shares104.21M158.69M219.33M235.23M241.03M
Weighted Avg Shares (Diluted)104.21M158.69M219.33M235.23M241.03M

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.